InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,867.60
(
-0.80%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.31
(
0.10%
)
Bitcoin
64,241.65
(
-0.06%
)
Post# of 1752
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

elbiatcho1

Send PM Follow Ignore
Followers 45
Posts 7066
Boards Moderated 0
Alias Born 02/05/2008

elbiatcho1

Re: opticalalert_com post# 1444

Wednesday, 01/04/2017 12:34:40 AM

Wednesday, January 04, 2017 12:34:40 AM

Post# of 1752
Kind of after-the-fact info.

Author talks of phase II data and eventually ends his idea with "There would be no need for phase III trials if the results of phase II trials were routinely regarded as definitive and practice changing."

Author is stating possible problems for future trials of whatever drug, hence "Future Challenges for Drug Development...". Perhaps forward looking to the many phase 2 studies that are ongoing:
http://www.exelixis.com/sites/default/files/pdf/Cabozantinib%20Clinical%20Trials%20-%20November%202016.pdf




Anyways, EXEL posted options news today? Seems they're looking long term.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent EXEL News
More EXEL News
InvestorsHub NewsWire

Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM

North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM

Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM

Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM

BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM

Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM

Start posting your company's news
Only $200 per official company press release!